Overview

Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status:
Completed

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) and to examine its effectiveness in eliminating residual diffuse large B-Cell Lymphoma (DLBCL) in patients.

Phase:

Phase 2

Details

Lead Sponsor:

C. Babis Andreadis

Collaborators:

GlaxoSmithKline
University of California, San Francisco

Treatments:

Cytarabine
Etoposide
Etoposide phosphate
Ofatumumab